KTTA Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
5.7M
+17.2%
4.9M
-52.5%
10.3M
+229.8%
3.1M
-18.4%
3.8M
R&D
3.7M
+25.3%
2.9M
+7.2%
2.7M
+102.2%
1.4M
-36.8%
2.1M
SG&A
2.0M
+4.8%
1.9M
-74.2%
7.5M
+328.7%
1.8M
+5.4%
1.7M
Operating Income
-5713282
-17.2%
-4876644
+52.5%
-10256162
-229.8%
-3110055
+18.4%
-3810899
EBITDA
-5870823
-24.4%
-4719103
+53.3%
-10098621
-244.8%
-2928463
+26.1%
-3964891
Net Income
-5273852
-83.8%
-2869482
+71.6%
-10110868
-232.9%
-3037420
+18.3%
-3716157
EPS (Basic)
$-0.16
-33.3%
$-0.12
+84.8%
$-0.79
-92.7%
$-0.41
+37.9%
$-0.66
EPS (Diluted)
$-0.16
-33.3%
$-0.12
+84.8%
$-0.79
-92.7%
$-0.41
+37.9%
$-0.66
Shares (Diluted)
32.1M
+31.9%
24.3M
+89.7%
12.8M
+72.3%
7.4M
+31.9%
5.6M
Pasithea Therapeutics (KTTA) — Financials